

# Directorate Change

RNS Number : 9117F

Novacyt S.A.

10 November 2022

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Directorate change

Paris, France and Camberley, UK - 10 November 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that David Allmond is stepping down as Chief Executive Officer (CEO) and a member of the Board of Novacyt, with immediate effect, to enable him to pursue other business opportunities. James McCarthy, currently the Company's Chief Financial Officer (CFO), will assume the role of Acting CEO until a successor is appointed. Steve Gibson, Group Finance Director, will take on a substantial part of the CFO responsibilities to assist James in this period.

The Company remains focused on executing its post-COVID-19 growth strategy to become a leading, global clinical diagnostics company in the fight against infectious diseases through product portfolio expansion, geographic expansion, and business development.

James Wakefield, Non-Executive Chairman of Novacyt, commented:

"On behalf of the Board, I would like to thank Dave for his focus on helping to formulate a post-COVID-19 strategy for the Company and wish him well in his future endeavours. We will continue to progress this strategy to become a leading, global clinical diagnostics company in the fight against infectious diseases."

The information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under Article 7 of the Market Abuse Regulation (EU) No. 596/2014 (as amended) as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

- End -

## Contacts

### Novacyt SA

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Numis (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

[r.durgetto@allegrafinance.com](mailto:r.durgetto@allegrafinance.com) / [y.petit@allegrafinance.com](mailto:y.petit@allegrafinance.com)

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

[victoria.fostermitchell@fticonsulting.com](mailto:victoria.fostermitchell@fticonsulting.com) / [Alex.Shaw@fticonsulting.com](mailto:Alex.Shaw@fticonsulting.com) / [Novacyt.group@fticonsulting.com](mailto:Novacyt.group@fticonsulting.com)

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

[arnaud.decheffontaines@fticonsulting.com](mailto:arnaud.decheffontaines@fticonsulting.com)

## About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com). RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABLBJTMTBMTFT